FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297902606> ?p ?o ?g. }

• W4297902606 endingPage "932" @default.
• W4297902606 startingPage "928" @default.
• W4297902606 abstract "•Lenalidomide and other immunomodulatory drugs (IMiDs), routinely used for the treatment of multiple myeloma (MM), are frequently associated with skin toxicities that appear to be T helper 2 (Th2)-mediated. •Dupilumab, a human monoclonal antibody FDA-approved for the treatment of Th2-driven atopic conditions, has shown clinical utility in treating lenalidomide-associated skin toxicities. Dupilumab targets the IL-4 receptor alpha chain (IL-4Rα), thereby inhibiting IL-4 and IL-13 signaling, with resultant blockade of Th2 inflammation specifically as opposed to broad immunosuppression. •Increased activity of IL-4 and IL-13 has been closely associated with malignancy due to the roles of these cytokines in carcinogenesis and modulation of tumor immunosurveillance. Dupilumab, by blocking both of these cytokines, may potentially be tumor-protective in MM patients. •In this case series of three MM patients treated with dupilumab for lenalidomide rashes, remitted MM in one patient remained stable for 19 months while on dupilumab alone and, shortly after discontinuing this agent, rapid disease progression was observed. A second patient remained in remission with dupilumab treatment for 15 months, the latter 12 of which were without concurrent maintenance therapy. A third patient was initiated on dupilumab while receiving induction therapy for MM and, with both treatments simultaneously, achieved normalization of MM blood markers. •Dupilumab is an effective therapy for IMiD-mediated eczematous rashes; furthermore, it may have therapeutic benefits as adjuvant therapy for MM. If confirmed, its use stands to provide a significant benefit for these patients’ quality of life and overall prognosis. •Lenalidomide and other immunomodulatory drugs (IMiDs), routinely used for the treatment of multiple myeloma (MM), are frequently associated with skin toxicities that appear to be T helper 2 (Th2)-mediated. •Dupilumab, a human monoclonal antibody FDA-approved for the treatment of Th2-driven atopic conditions, has shown clinical utility in treating lenalidomide-associated skin toxicities. Dupilumab targets the IL-4 receptor alpha chain (IL-4Rα), thereby inhibiting IL-4 and IL-13 signaling, with resultant blockade of Th2 inflammation specifically as opposed to broad immunosuppression. •Increased activity of IL-4 and IL-13 has been closely associated with malignancy due to the roles of these cytokines in carcinogenesis and modulation of tumor immunosurveillance. Dupilumab, by blocking both of these cytokines, may potentially be tumor-protective in MM patients. •In this case series of three MM patients treated with dupilumab for lenalidomide rashes, remitted MM in one patient remained stable for 19 months while on dupilumab alone and, shortly after discontinuing this agent, rapid disease progression was observed. A second patient remained in remission with dupilumab treatment for 15 months, the latter 12 of which were without concurrent maintenance therapy. A third patient was initiated on dupilumab while receiving induction therapy for MM and, with both treatments simultaneously, achieved normalization of MM blood markers. •Dupilumab is an effective therapy for IMiD-mediated eczematous rashes; furthermore, it may have therapeutic benefits as adjuvant therapy for MM. If confirmed, its use stands to provide a significant benefit for these patients’ quality of life and overall prognosis." @default.
• W4297902606 created "2022-10-01" @default.
• W4297902606 creator A5017982675 @default.
• W4297902606 creator A5028046297 @default.
• W4297902606 creator A5030726651 @default.
• W4297902606 creator A5042665600 @default.
• W4297902606 creator A5052002610 @default.
• W4297902606 creator A5063927988 @default.
• W4297902606 creator A5081077809 @default.
• W4297902606 creator A5087455345 @default.
• W4297902606 date "2022-12-01" @default.
• W4297902606 modified "2023-09-23" @default.
• W4297902606 title "Dupilumab in Multiple Myeloma: A Case Series" @default.
• W4297902606 cites W1129332165 @default.
• W4297902606 cites W1538328956 @default.
• W4297902606 cites W2019881908 @default.
• W4297902606 cites W2043812762 @default.
• W4297902606 cites W2051593018 @default.
• W4297902606 cites W2082794354 @default.
• W4297902606 cites W2092844155 @default.
• W4297902606 cites W2149336558 @default.
• W4297902606 cites W2164937630 @default.
• W4297902606 cites W2167664605 @default.
• W4297902606 cites W2169611228 @default.
• W4297902606 cites W2293740089 @default.
• W4297902606 cites W2395837508 @default.
• W4297902606 cites W2407647427 @default.
• W4297902606 cites W2950260751 @default.
• W4297902606 cites W2973122049 @default.
• W4297902606 cites W3013413712 @default.
• W4297902606 cites W3046951841 @default.
• W4297902606 cites W3112934727 @default.
• W4297902606 doi "https://doi.org/10.1016/j.clml.2022.09.002" @default.
• W4297902606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36243663" @default.
• W4297902606 hasPublicationYear "2022" @default.
• W4297902606 type Work @default.
• W4297902606 citedByCount "2" @default.
• W4297902606 countsByYear W42979026062023 @default.
• W4297902606 crossrefType "journal-article" @default.
• W4297902606 hasAuthorship W4297902606A5017982675 @default.
• W4297902606 hasAuthorship W4297902606A5028046297 @default.
• W4297902606 hasAuthorship W4297902606A5030726651 @default.
• W4297902606 hasAuthorship W4297902606A5042665600 @default.
• W4297902606 hasAuthorship W4297902606A5052002610 @default.
• W4297902606 hasAuthorship W4297902606A5063927988 @default.
• W4297902606 hasAuthorship W4297902606A5081077809 @default.
• W4297902606 hasAuthorship W4297902606A5087455345 @default.
• W4297902606 hasConcept C126322002 @default.
• W4297902606 hasConcept C143998085 @default.
• W4297902606 hasConcept C16005928 @default.
• W4297902606 hasConcept C203014093 @default.
• W4297902606 hasConcept C2776063141 @default.
• W4297902606 hasConcept C2776364478 @default.
• W4297902606 hasConcept C2778329239 @default.
• W4297902606 hasConcept C2779824493 @default.
• W4297902606 hasConcept C71924100 @default.
• W4297902606 hasConceptScore W4297902606C126322002 @default.
• W4297902606 hasConceptScore W4297902606C143998085 @default.
• W4297902606 hasConceptScore W4297902606C16005928 @default.
• W4297902606 hasConceptScore W4297902606C203014093 @default.
• W4297902606 hasConceptScore W4297902606C2776063141 @default.
• W4297902606 hasConceptScore W4297902606C2776364478 @default.
• W4297902606 hasConceptScore W4297902606C2778329239 @default.
• W4297902606 hasConceptScore W4297902606C2779824493 @default.
• W4297902606 hasConceptScore W4297902606C71924100 @default.
• W4297902606 hasIssue "12" @default.
• W4297902606 hasLocation W42979026061 @default.
• W4297902606 hasLocation W42979026062 @default.
• W4297902606 hasOpenAccess W4297902606 @default.
• W4297902606 hasPrimaryLocation W42979026061 @default.
• W4297902606 hasRelatedWork W2052365909 @default.
• W4297902606 hasRelatedWork W2136773918 @default.
• W4297902606 hasRelatedWork W2344741804 @default.
• W4297902606 hasRelatedWork W2435227317 @default.
• W4297902606 hasRelatedWork W3113412439 @default.
• W4297902606 hasRelatedWork W3121407702 @default.
• W4297902606 hasRelatedWork W3126730168 @default.
• W4297902606 hasRelatedWork W3217566318 @default.
• W4297902606 hasRelatedWork W4224227857 @default.
• W4297902606 hasRelatedWork W4297237848 @default.
• W4297902606 hasVolume "22" @default.
• W4297902606 isParatext "false" @default.
• W4297902606 isRetracted "false" @default.
• W4297902606 workType "article" @default.